Copyright
©The Author(s) 2023.
World J Gastroenterol. Apr 21, 2023; 29(15): 2241-2260
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2241
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2241
Table 1 Cell free DNA involved in pancreatic cancer diagnostic and prognostics
Target candidate | Up/down | Sample | Potential value |
CEA mRNA | Up | Whole blood | D |
EGFR mRNA | Up | Serum | D |
4GnT mRNA | Up | Whole blood | D |
COL6A3 mRNA | Up | Serum | D/P |
Mir-155 | Up | Plasma | D |
miR-196a | Up | Plasma | D |
miR-21 | Up | Plasma | D |
miR-210 | Up | Plasma | D |
miR-155 | Up | Pancreatic juice | D |
miR-21 | Up | Plasma | D |
miR-196a | Up | Serum | D/P |
miR-200a | Up | Serum | D |
miR-200b | Up | Plasma | D |
miR-210 | Up | Plasma | D |
miR-18a | Up | Plasma | D/T |
miR-16 | Up | Plasma | D |
miR-196a | Up | Plasma | D |
miR-185 | Up | Serum | D |
miR-191 | Up | Serum | D |
miR-20a | Up | Serum | D |
miR-21 | Up | Serum | D/P |
miR-24 | Up | Serum | D |
miR-25 | Up | Serum | D |
miR-99a | Up | Serum | D |
miR-1290 | Up | Serum | D |
miR-221 | Up | Plasma | D/T/P |
miR-375 | Down | Plasma | D/T/P |
miR-375 | Up | Plasma | D |
miR-27a3p | Up | Whole blood | D |
miR-196a | Up | Serum | D |
miR-196b | Up | Serum | D |
miR-205 | Up | Pancreatic juice | D/P |
miR-210 | Up | Saliva | D/P |
miR-492 | Up | Plasma | D/P |
miR-1427 | Up | Plasma | D/P |
miR-22 | Up | Plasma | D |
miR-642b | Up | Plasma | D |
miR-885-5p | Up | Plasma | D |
Multigene index | Up | Whole blood | D |
miR-483-3p | Up | Plasma | D |
MIR-21 | Up | Serum | D |
MIR-210 | Down | Serum | D |
MIR-155 | Up | Serum | D |
miR-222 | Down | Serum | D |
miR-203 | Down | Serum | D |
miR-132 | Down | Serum | D |
miR-212 | Down | Serum | D |
miR-96 | Down | Serum | D |
mi-126 | Down | Serum | D |
mi-217 | Down | Serum | D |
Let-7 | Down | Serum | D |
miR-144 | Down | Serum | D |
miR-148 | Down | Serum | D |
miR-34a | Down | Serum | D |
miR-3548 | Up | Serum | D |
Table 2 Cell free protein (secreted proteome) involved in pancreatic cancer diagnostic and prognostics
Target candidate | Up/down | Sample | Target | Pathway | Potential value |
ADAMTS1 | Up | Plasma | ADAMTS1 | Methylation | D |
BNC1 | Up | Plasma | BNC1 | Methylation | D |
CDKN1C | Up | Plasma | CDKN1C | Methylation | D |
MLH1 | Down | Plasma | MLH1 | Mutation | D |
PGR (prox) | Up | Plasma | PGR | Cell signaling | D |
SYK | Up | Plasma | SYK protein, mRNA | Cell signaling | D |
CCND2 | Up | Plasma | Cyclin D2 | Cell signaling | D |
ALX4 | Up | Plasma | Transcription factor | Mutation | P |
APC | Down | Plasma | APC | Mutation | P |
BMP3 | Up | Plasma | TGFβ | Cell signaling | P |
BNC1 | Up | Plasma | BNC1 | Cell signaling | P |
BRCA1 | Up | Plasma | BRCA1 | Mutation | P |
CDKN2B | Up | Plasma | Ink4, p16, p14 | Cell signaling | P |
CHFR | Up | Plasma | E3 Ubiquitin-protein | Cell signaling, check point | P |
ESR1 | Up | Plasma | ESR1, Transcription factor | Cell signaling | P |
EYA2 | Up | Plasma | EYA2 | Cell cycle | P |
GSTP1 | Up | Plasma | GSTP1 | Cell signaling | P |
HIC1 | Up | Plasma | HIC ZBTB TRANSCRIPTIONAL RECEPTOR 1 | Cell signaling | P |
MEST1v2 | Up | Plasma | Alpha/Beta hydrolase superfamily | Cell signaling | P |
Foxe1 | Down | Pancreatic juice | Foxe1 | Methylation | D |
MGMT | Up | Plasma | MGMT | Methylation | P |
MLH1 | Up | Plasma | MLH1 | Mutation | P |
NPTX2 | Up | Pancreatic juice | NP, synaptic proteins | Cell signaling | P |
NEUROG1 | Up | Plasma | NEUROG1 | Cell signaling, regulatory network | P |
RARB | Up | Plasma | RARB | Cell signaling | P |
RASSF1A | Down | Plasma | RAS effector protein | Methylation | P |
SFRP2 | Up | Plasma | SFRP2 | Wnt signaling | P |
SEPT9v2 | Up | Plasma | Septin9 | Cell cycle | P |
CDID | Up | Pancreatic juice | CDID | Methylation | D |
PRKC | Up | Pancreatic juice | PRKC | Methylation | D |
IKZF1 | Up | Pancreatic juice | IKZF1 | Methylation | D |
KCNK12 | Up | Pancreatic juice | KCNK12 | Methylation | D |
CLEC11A | Up | Pancreatic juice | CLEC11A | Methylation | D/P |
NDRG4 | Up | Pancreatic juice | NDRG4 promoter | Methylation | D |
SST | Up | Plasma | SST | Downstream signaling, transcriptional regulation | P |
TFPI2 | Up | Pancreatic juice | TFPI2 | Gene silencing, cell adhesion plasmin signaling | P |
TAC1 | Up | Plasma | TAC1 | Gpcr downstream, signal transduction | P |
VIM | Up | Plasma | Vimentin | Cell signaling | P |
WNT5A | Up | Plasma | WNT5A | Wnt signaling | P |
PENK | Up | Pancreatic juice | Proenkephalin | Apoptotic, downstream signaling | |
DCC | Down | Plasma | Netrin-1 Receptor | Mutation | D |
P16 | Down | Pancreatic juice | CDKN2A | Mutation, cell cycle regulation | D |
P14 | Down | Plasma | CDKN2A | Cell cycle | D |
DNMT1 | Up | Plasma | DNMT1 | Mutation | D |
DNMT3A | Up | Plasma | DNMT3A | Methylation | D |
DNMT3B | Up | Plasma | DNA | Methylation | D |
Table 3 Cell-free RNA involved in pancreatic cancer diagnostic and prognostics
Target candidate | Up/down | Sample | Target | Pathway | Potential value |
ERBB2 | Up | Plasma | Ch 12, KRAS | Mutation | D |
CDKN2A | Down | Plasma | Gene, Ch 9p21 | Mutation | D |
SMAD4 | Down | Plasma | TGFβ | Cell signaling | D |
TP53 | Down | Plasma | P53 protein | Mutation/cell signaling | D |
EGFR | Up | Plasma | Exon 19, 21 | Cell signaling/mutation | D |
PBRM1 | Down | Plasma | SWI/SNF ch remodeling comp | Mutation, immune checkpoint blockade | D |
KMT2D | Down | Plasma | FOX1-miR-1224, HIF/GATA5-miR-133a | Mutation | D |
RNF43 | Down | Plasma | RNF43PROTEIN | Wnt signaling | D |
TP63 | Down | Plasma | P63 protein | Cell signaling | D |
MTOR | Up | Plasma | mTOR | mTOR signaling | D |
NRAS | Up | Plasma | NRAS | Mutation | D |
HRAS | Up | Plasma | HRAS | Mutation | D |
BRCA1 | Down | Plasma | BRCA1 | Signaling | D |
BRCA2 | Down | Plasma | BRCA2 | Signaling | D |
PALB2 | Up | Plasma | PALB2 | Signaling/mutation | D |
GPC1 | Up | Serum | MAPK, PI3K-AKT-mTOR, Hedgehog signaling | Cell signaling | D |
PFAA | Up | Serum | MAPK, PI3K-AKT-mTOR, Hedgehog signaling | Cell signaling | D |
OPNT+TIMP-1 | Up | Serum | MAPK, PI3K-AKT-mTOR, signaling | Cell signaling | D |
CPA4 | Up | Serum | MAPK, mTOR, Hedgehog signaling | Cell signaling | D |
MUC5 AC | Up | Urine/pancreatic juice | MAPK, PI3K-AKT-mTOR, Hedgehog signaling | Cell signaling | D/P |
C4BPA | Up | Serum | MAPK, PI3K-AKT-mTOR, Hedgehog signaling | Cell signaling | D |
OPN | Up | Serum | OPN | Cell signaling | P |
TIMP-1 | Up | Serum | TIMP-1 | Cell signaling | D |
NGAL | Up | Urine | Receptor binding protein | Cell signaling | D |
ARG2 | Down | Pancreatic juice | Beta cell function | Cell signaling | D |
LYVE-1 | Up | Urine | Receptor binding glycoprotein | D | |
TFF1 | Up | Urine | Regulation of transcription factor | Promoter modeling | D |
REG1A | Up | Urine | REG1A protein | Cell signaling | D |
Table 4 Cell-free biomarkers involved in distinguishing pancreatic cancer from other pancreatic benign diseases
Biomarkers | CP | AIP | PanIN | IPMN | MCN |
PENK DNA | Yes | No | Yes | Yes | Yes |
CUX2 | Yes | No | No | No | No |
REGIA | Yes | No | No | No | No |
TFP12 | Yes | No | Yes | Yes | Yes |
FOXE1 | Yes | No | Yes | Yes | Yes |
P16 | Yes | No | Yes | Yes | Yes |
NPTX2 | Yes | No | Yes | Yes | Yes |
PENK | Yes | No | Yes | Yes | Yes |
CYCLIN D2 | Yes | No | Yes | Yes | Yes |
CDO1 | No | Yes | No | No | No |
HAS-mIR-23a | No | No | No | Yes | No |
HAS-mIR-23b | No | No | No | Yes | No |
HAS-mIR-210 | Yes | No | No | No | No |
Let-7c | Yes | No | No | No | No |
S100A9 | Yes | No | No | No | No |
BNCI | No | No | Yes | No | No |
ADAMTS1 | No | No | No | No | No |
BNC1 | No | No | No | No | No |
9-Sep | No | No | No | No | No |
GPC1 | No | No | No | No | No |
PFAA | No | No | No | No | No |
OPNT + TIMP-1 | No | No | No | No | No |
CPA4 | No | No | No | No | No |
MUC5 AC | No | No | No | No | No |
C4BPA | No | No | No | No | No |
- Citation: Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A, Sikdar N. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World J Gastroenterol 2023; 29(15): 2241-2260
- URL: https://www.wjgnet.com/1007-9327/full/v29/i15/2241.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i15.2241